Gilead Sciences, Inc.
333 Lakeside Dr
Foster City, CA 94404-1147
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific. Advancing Therapeutics, Improving Lives Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions. Our portfolio of 15 marketed products includes a number of category firsts, including the only complete treatment regimens for HIV infection available in a once-daily single pill ? Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), approved in 2006; Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate), approved in 2011; and Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), approved in 2012 ? as well as the first product, Truvada® (emtricitabine/tenofovir disoproxil fumarate), approved in 2012 for HIV prevention in uninfected adults at high risk, a strategy known as pre-exposure prophylaxis (PrEP).
Clinical Development Stage
Approved; IND; NDA; Phase I; Phase II; Phase III; PreClinical